ERBB2 and neoplasm: Based on the results obtained in Myd88−/− mice, the authors suggested that anti-HER2/neu antibody could induce HMGB-1 release in the tumor microenvironment, which enhanced innate responses via the MyD88 pathway and promoted the priming of adaptive immune cells, leading to an increased tumor clearance (17).